Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HemeRX is a topical formulation of racemic epinephrine delivered in the form of medicated pellets, specifically designed for use in restorative dentistry. It is primarily utilized for gingival retraction and local hemostasis (bleeding control) during procedures such as the preparation and placement of dental crowns. As a non-selective adrenergic agonist, it induces local vasoconstriction by stimulating alpha-adrenergic receptors in the gingival tissue. The University of Washington has investigated HemeRX in pediatric populations to assess its cardiovascular safety, specifically monitoring for systemic absorption that could affect heart rate and blood pressure in children undergoing dental treatment under general anesthesia.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on HemeRX.